Display options
Cite
Ollert MW, David K, Schmitt C, et al. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci U S A. 1996;93(9):4498-503doi: 10.1073/pnas.93.9.4498.
Ollert, M. W., David, K., Schmitt, C., Hauenschild, A., Bredehorst, R., Erttmann, R., & Vogel, C. W. (1996). Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 93(9), 4498-503. https://doi.org/10.1073/pnas.93.9.4498
Ollert, M W, et al. "Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells." Proceedings of the National Academy of Sciences of the United States of America vol. 93,9 (1996): 4498-503. doi: https://doi.org/10.1073/pnas.93.9.4498
Ollert MW, David K, Schmitt C, Hauenschild A, Bredehorst R, Erttmann R, Vogel CW. Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4498-503. doi: 10.1073/pnas.93.9.4498. PMID: 8633097; PMCID: PMC39567.
Copy Download .nbib Format: NLM
Share it on
Full text links
Atypon Free PMC Article

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4498-503. doi: 10.1073/pnas.93.9.4498.

Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells.

Proceedings of the National Academy of Sciences of the United States of America

M W Ollert, K David, C Schmitt, A Hauenschild, R Bredehorst, R Erttmann, C W Vogel

Affiliations

  1. Department of Biochemistry and Molecular Biology, University of Hamburg, Germany.

PMID: 8633097 PMCID: PMC39567 DOI: 10.1073/pnas.93.9.4498
Free PMC Article

Abstract

Neuroblastoma (NB) is characterized by the second highest spontaneous regression of any human malignant disorder, a phenomenon that remains to be elucidated. In this study, a survey of 94 normal human adult sera revealed a considerable natural humoral cytotoxicity against human NB cell lines in approximately one-third of the tested sera of both genders. Specific cell killing by these sera was in the range of 40% to 95%. Serum cytotoxicity was dependent on an intact classical pathway of complement. By several lines of evidence, IgM antibodies were identified as the cytotoxic factor in the sera. Further analyses revealed that a 260-kDa protein was recognized by natural IgM of cytotoxic sera in Western blots of NB cell extracts. The antigen was expressed on the surface of seven human NB cell lines but not on human melanoma or other control tumor cell lines derived from kidney, pancreas, colon, bone, skeletal muscle, lymphatic system, and bone marrow. Furthermore, no reactivity was observed with normal human fibroblasts, melanocytes, and epidermal keratinocytes. The antigen was expressed in vivo as detected by immunohistochemistry in both the tumor of a NB patient and NB tumors established in nude rats from human NB cell lines. Most interestingly, the IgM anti-NB antibody was absent from the sera of 11 human NB patients with active disease. The anti-NB IgM also could not be detected in tumor tissue obtained from a NB patient. Collectively, our data suggest the existence of a natural humoral immunological tumor defense mechanism, which could account for the in vivo phenomenon of spontaneous NB tumor regression.

Cited by

Shibad V, Bootwala A, Mao C, Bader H, Vo H, Landesman-Bollag E, Guo C, Rubio A, Near R, Gao W, Challa S, Chukka V, Gao J, Kelly A, Landesman T, VanHelene T, Zhong X.
Front Immunol. 2021 Sep 23;12:722451. doi: 10.3389/fimmu.2021.722451. eCollection 2021.
PMID: 34630396

References

  1. Cancer Immunol Immunother. 1989;29(3):171-8 - PubMed
  2. Am J Pathol. 1963 Dec;43:1089-104 - PubMed
  3. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5407-11 - PubMed
  4. J Immunol Methods. 1984 Oct 12;73(1):203-20 - PubMed
  5. Cancer Res. 1985 Jun;45(6):2642-9 - PubMed
  6. Proc Natl Acad Sci U S A. 1968 Aug;60(4):1231-8 - PubMed
  7. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
  8. Natl Cancer Inst Monogr. 1976 Nov;44:131-4 - PubMed
  9. In Vitro. 1979 Jun;15(6):401-8 - PubMed
  10. J Exp Med. 1979 Sep 19;150(3):564-79 - PubMed
  11. Cancer Res. 1986 Aug;46(8):4116-20 - PubMed
  12. Arch Surg. 1989 Feb;124(2):235-9 - PubMed
  13. Adv Immunol. 1989;47:117-85 - PubMed
  14. Infect Immun. 1990 Mar;58(3):625-31 - PubMed
  15. J Immunol. 1990 May 15;144(10):3862-7 - PubMed
  16. Mol Immunol. 1990 Oct;27(10):957-64 - PubMed
  17. Cancer Invest. 1990;8(6):603-11 - PubMed
  18. Immunol Today. 1991 May;12(5):154-9 - PubMed
  19. Cancer Metastasis Rev. 1991 Dec;10(4):321-33 - PubMed
  20. Cancer Res. 1993 Feb 1;53(3):592-9 - PubMed
  21. Science. 1993 May 14;260(5110):976-9 - PubMed
  22. Cancer Res. 1993 Oct 15;53(20):4978-86 - PubMed
  23. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8972-6 - PubMed
  24. Immunol Today. 1993 Oct;14(10):480-2 - PubMed
  25. J Immunol. 1994 Feb 15;152(4):1727-37 - PubMed
  26. J Immunol. 1994 Aug 1;153(3):1386-95 - PubMed
  27. J Immunol. 1994 Sep 1;153(5):2213-21 - PubMed
  28. J Clin Pathol. 1983 Jan;36(1):114-5 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources